The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes

Breast Cancer Research and Treatment

Volumn 150, Issue 2, 2015, Pages 427-437

  Vissers, Pauline A J ^a,b   Cardwell, Chris R ^c   van de Poll Franse, Lonneke V ^a,b   Young, Ian S ^c   Pouwer, Frans ^a   Murray, Liam J ^c  

^a TILBURG UNIVERSITY   (Netherlands)

^b Eindhoven Cancer Registry   (Netherlands)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Breast cancer; Diabetes; Glucose lowering drugs; Insulin; Metformin; Sulphonylurea derivatives

Indexed keywords

ANTIDIABETIC AGENT; METFORMIN;

AGED; BREAST NEOPLASMS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMAN; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84925405909     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3331-5     Document Type: Article

References (35)

1. Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B (2005) Diabetes mellitus and breast cancer. Lancet Oncol 6(2):103–111. doi:10.1016/s1470-2045(05)01736-5
2. van de Poll-Franse LV, Houterman S, Janssen-Heijnen ML, Dercksen MW, Coebergh JW, Haak HR (2007) Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis. Int J Cancer 120(9):1986–1992. doi:10.1002/ijc.22532
3. De Bruijn KM, Arends LR, Hansen BE, Leeflang S, Ruiter R, van Eijck CH (2013) Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. Br J Surg 100(11):1421–1429. doi:10.1002/bjs.9229
4. Peairs KS, Barone BB, Snyder CF, Yeh HC, Stein KB, Derr RL, Brancati FL, Wolff AC (2011) Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol 29(1):40–46. doi:10.1200/jco.2009.27.3011
5. Du Y, Zheng H, Wang J, Ren Y, Li M, Gong C, Xu F, Yang C (2014) Metformin inhibits histone H2B monoubiquitination and downstream gene transcription in human breast cancer cells. Oncol Lett 8(2):809–812. doi:10.3892/ol.2014.2158
6. Queiroz EA, Puukila S, Eichler R, Sampaio SC, Forsyth HL, Lees SJ, Barbosa AM, Dekker RF, Fortes ZB, Khaper N (2014) Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells. PLoS One 9(5):e98207. doi:10.1371/journal.pone.0098207
7. Col NF, Ochs L, Springmann V, Aragaki AK, Chlebowski RT (2012) Metformin and breast cancer risk: a meta-analysis and critical literature review. Breast Cancer Res Treat 135(3):639–646. doi:10.1007/s10549-012-2170-x
8. Bosco JL, Antonsen S, Sorensen HT, Pedersen L, Lash TL (2011) Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark. Cancer Epidemiol Biomark Prev 20(1):101–111. doi:10.1158/1055-9965.epi-10-0817
9. Chlebowski RT, McTiernan A, Wactawski-Wende J, Manson JE, Aragaki AK, Rohan T, Ipp E, Kaklamani VG, Vitolins M, Wallace R, Gunter M, Phillips LS, Strickler H, Margolis K, Euhus DM (2012) Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol 30(23):2844–2852. doi:10.1200/jco.2011.39.7505
10. He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee MH, Yeung SC (2012) Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol 23(7):1771–1780. doi:10.1093/annonc/mdr534
11. Lega IC, Austin PC, Gruneir A, Goodwin PJ, Rochon PA, Lipscombe LL (2013) Association between metformin therapy and mortality after breast cancer: a population-based study. Diabetes Care 36(10):3018–3026. doi:10.2337/dc12-2535
12. Oppong BA, Pharmer LA, Oskar S, Eaton A, Stempel M, Patil S, King TA (2014) The effect of metformin on breast cancer outcomes in patients with type 2 diabetes. Cancer Med 3(4):1025–1034. doi:10.1002/cam4.259
13. Bayraktar S, Hernadez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, Hortobagyi GN, Gonzalez-Angulo AM (2012) Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 118(5):1202–1211. doi:10.1002/cncr.26439
14. Suissa S, Azoulay L (2012) Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 35(12):2665–2673. doi:10.2337/dc12-0788
15. Hou G, Zhang S, Zhang X, Wang P, Hao X, Zhang J (2013) Clinical pathological characteristics and prognostic analysis of 1013 breast cancer patients with diabetes. Breast Cancer Res Treat 137(3):807–816. doi:10.1007/s10549-012-2404-y
16. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL (2012) Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 35(2):299–304. doi:10.2337/dc11-1313
17. Jick H, Jick SS, Derby LE (1991) Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 302(6779):766–768. doi:10.1136/bmj.302.6779.766
18. Khan NF, Perera R, Harper S, Rose PW (2010) Adaptation and validation of the Charlson index for Read/OXMIS coded databases. BMC Fam Pract 11:1. doi:10.1186/1471-2296-11-1
19. British Medical Association and the Royal Pharmaceutical Society of Great Britain (2013) British National Formulary, http://www.bnf.org/bnf/index.htm
20. Chubak J, Boudreau DM, Wirtz HS, McKnight B, Weiss NS (2013) Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival. J Natl Cancer Inst 105(19):1456–1462. doi:10.1093/jnci/djt211
21. Kirkwood BR, Sterne JAC (2003) Essential medical statistics, 2nd edn. Blackwell publishing, Hoboken
22. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N (2007) Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67(22):10804–10812. doi:10.1158/0008-5472.can-07-2310
23. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66(21):10269–10273. doi:10.1158/0008-5472.can-06-1500
24. Rocha GZ, Dias MM, Ropelle ER, Osório-Costa F, Rossato FA, Vercesi AE, Saad MJA, Carvalheira JBC (2011) Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. Clin Cancer Res 17(12):3993–4005. doi:10.1158/1078-0432.ccr-10-2243
25. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27(20):3297–3302. doi:10.1200/jco.2009.19.6410
26. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F (2012) Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 122(6):253–270. doi:10.1042/cs20110386
27. Duggan C, Wang CY, Neuhouser ML, Xiao L, Smith AW, Reding KW, Baumgartner RN, Baumgartner KB, Bernstein L, Ballard-Barbash R, McTiernan A (2013) Associations of insulin-like growth factor and insulin-like growth factor binding protein-3 with mortality in women with breast cancer. Int J Cancer 132(5):1191–1200. doi:10.1002/ijc.27753
28. Sarkissyan S, Sarkissyan M, Wu Y, Cardenas J, Koeffler HP, Vadgama JV (2014) IGF-1 regulates Cyr61 induced breast cancer cell proliferation and invasion. PLoS One 9(7):e103534. doi:10.1371/journal.pone.0103534
29. Goodwin P, Stambolic V, Lemieux J, Chen B, Parulekar W, Gelmon K, Hershman D, Hobday T, Ligibel J, Mayer I, Pritchard K, Whelan T, Rastogi P, Shepherd L (2011) Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 126(1):215–220. doi:10.1007/s10549-010-1224-1
30. NCIC Clinical Trials Group, National Cancer Institute, A Phase III Randomized Trial of Metformin versus Placebo in Early Stage Breast Cancer. ClinicalTrials.gov [Internet]. https://clinicaltrials.gov/ct2/show/NCT01101438. NLM Identifier: NCT01101438
31. Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29(2):254–258. doi:10.2337/diacare.29.02.06.dc05-1558
32. McCoubrie R, Jeffrey D, Paton C, Dawes L (2005) Managing diabetes mellitus in patients with advanced cancer: a case note audit and guidelines. Eur J Cancer Care 14(3):244–248. doi:10.1111/j.1365-2354.2005.00564.x
33. Rendell M (2004) The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 64(12):1339–1358. doi:10.2165/00003495-200464120-00006
34. Ferguson RD, Novosyadlyy R, Fierz Y, Alikhani N, Sun H, Yakar S, Leroith D (2012) Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes. Breast Cancer Res 14(1):R8. doi:10.1186/bcr3089
35. Perseghin G, Calori G, Lattuada G, Ragogna F, Dugnani E, Garancini MP, Crosignani P, Villa M, Bosi E, Ruotolo G, Piemonti L (2012) Insulin resistance/hyperinsulinemia and cancer mortality: the Cremona study at the 15th year of follow-up. Acta Diabetol 49(6):421–428. doi:10.1007/s00592-011-0361-2